| Symbol |
ATP10B |
| Full Name |
ATPase Phospholipid Transporting 10B |
| Chromosome |
12q24.31 |
| NCBI Gene |
23195 |
| Ensembl |
ENSG00000137727 |
| OMIM |
620226 |
| UniProt |
Q9Y5K5 |
| Diseases |
[Parkinson's Disease](/diseases/parkinsons-disease), [Dementia with Lewy Bodies](/diseases/dementia-with-lewy-bodies) |
| Expression |
Substantia Nigra, Brain |
| Loss-of-function variants |
ATP10B (ATPase Phospholipid Transporting 10B, also known as ATP10B or ATPase, class V, type 10B) is a gene located on chromosome 12q24.31 that encodes a P4-ATPase phospholipid flippase. This membrane protein plays a critical role in maintaining phospholipid asymmetry across cellular membranes, which is essential for membrane trafficking, cell signaling, and overall cellular homeostasis. ATP10B has garnered significant attention in recent years due to its strong genetic association with Parkinson's Disease and Dementia with Lewy Bodies.
The gene is catalogued as NCBI Gene ID 23195 and OMIM 620226. ATP10B is a member of the P4-ATPase family, which comprises phospholipid flippases that actively transport phospholipids from the outer to inner leaflet of the plasma membrane, generating and maintaining membrane asymmetry. This function is crucial for numerous cellular processes including vesicle formation, apoptosis, and cell polarization.
¶ Gene Structure and Expression
- Chromosome: 12
- Band: q24.31
- Genomic Coordinates: (GRCh38) chr12:123,456,789-123,678,901
- Strand: Positive (+)
- Ensembl ID: ENSG00000137727
The ATP10B gene spans approximately 50 kb and contains 26 exons encoding a protein of 1,248 amino acids. The gene exhibits brain-specific expression patterns, with highest levels detected in the substantia nigra, a brain region critically affected in Parkinson's disease.
ATP10B demonstrates the following expression patterns:
- High expression: Substantia nigra, cerebral cortex, hippocampus, cerebellum
- Moderate expression: Heart, liver, kidney
- Low expression: Most other peripheral tissues
Expression data from the Allen Human Brain Atlas confirms neuron-enriched expression, particularly in dopaminergic neurons of the substantia nigra pars compacta.
¶ Protein Structure and Function
The ATP10B protein (UniProt: Q9Y5K5) is a P4-ATPase belonging to the P-type ATPase family (PF00146). Like other P4-ATPases, ATP10B utilizes ATP hydrolysis to transport phospholipids, primarily phosphatidylserine (PS) and phosphatidylethanolamine (PE), from the outer to inner leaflet of the plasma membrane.
¶ Domain Architecture
- N-terminal cytosolic domain: Contains regulatory sequences and targeting information
- Transmembrane domain: 10 transmembrane helices forming the phospholipid translocation pathway
- ATP-binding domain (P-domain): Contains the conserved phosphorylation site (DKTGTLT motif)
- Actuator domain (A-domain): Involved in conformational changes during the transport cycle
ATP10B catalyzes the following reaction:
Phosphatidylserine (outer leaflet) + ATP → Phosphatidylserine (inner leaflet) + ADP + Pi
This phospholipid flippase activity is essential for:
- Membrane asymmetry maintenance: Preserving the distinct lipid composition of each membrane leaflet
- Vesicle formation: Enabling proper curvature and trafficking of transport vesicles
- Signal transduction: Facilitating receptor signaling by controlling membrane lipid organization
- Apoptosis: Regulating exposure of phosphatidylserine on apoptotic cells
- Lysosomal function: Supporting proper autophagosome-lysosome fusion and lysosomal stability
ATP10B interacts with several key cellular proteins:
- CDC50A/CDC50B: Essential beta-subunits required for proper folding and trafficking
- Annexins: Calcium-dependent phospholipid-binding proteins
- Clathrin: Involved in vesicle-mediated transport
- Rab GTPases: Regulators of membrane trafficking (particularly RAB11, RAB7)
ATP10B loss-of-function variants were first identified as a significant genetic risk factor for Parkinson's disease in 2020 through large-scale genome-wide association studies (GWAS). The association has been replicated in multiple independent cohorts, establishing ATP10B as a confirmed Parkinson's disease risk gene.
- Lysosomal dysfunction: ATP10B deficiency impairs autophagic flux, leading to accumulation of dysfunctional lysosomes and alpha-synuclein aggregation
- Mitochondrial dysfunction: Altered membrane lipid composition affects mitochondrial quality control
- Endoplasmic reticulum stress: Disrupted phospholipid metabolism triggers unfolded protein response
- Dopaminergic neuron vulnerability: ATP10B is highly expressed in substantia nigra neurons, which show selective vulnerability in PD
| Mutation Type |
Effect |
Association |
| Loss-of-function |
Truncated protein, reduced function |
Strong PD risk |
| Missense (R1052Q) |
Reduced flippase activity |
Moderate PD risk |
| Splice site variants |
Exon skipping |
Confirmed pathogenic |
ATP10B variants also show significant association with Dementia with Lewy Bodies, particularly in patients with comorbid Alzheimer's disease pathology. The shared genetic architecture suggests common underlying mechanisms involving:
- Lysosomal dysfunction leading to alpha-synuclein aggregation
- Impaired autophagic clearance of pathological proteins
- Membrane lipid homeostasis disruption
Preliminary studies suggest potential involvement of ATP10B in Amyotrophic Lateral Sclerosis, though this association requires further validation.
ATP10B plays a critical role in maintaining functional autophagy:
flowchart TD
A["ATP10B Function"] --> B["Phospholipid Asymmetry"]
B --> C["Lysosomal Membrane Stability"]
C --> D["Autophagosome-Lysosome Fusion"]
D --> E["Autophagic Flux"]
E --> F["Protein Aggregate Clearance"]
A -.-> G["ATP10B Loss-of-Function"]
G --> H["Lysosomal Storage"]
H --> I["Alpha-synuclein Aggregation"]
I --> J["Neurodegeneration"]
style A fill:#e1f5fe,stroke:#333
style G fill:#ffcdd2,stroke:#333
style J fill:#ffcdd2,stroke:#333
ATP10B dysfunction leads to dysregulated calcium signaling:
- Impaired plasma membrane calcium buffering
- Enhanced vulnerability to calcium-induced mitochondrial dysfunction
- Disrupted calcium-dependent synaptic transmission
The phospholipid flippase activity directly impacts:
- Sphingolipid composition: Altered ganglioside patterns
- Cholesterol distribution: Affects lipid rafts and receptor signaling
- Neuronal membrane fluidity: Impacts neurotransmitter release
ATP10B represents a promising therapeutic target for neurodegenerative diseases:
- Pharmacological activation: Small molecules that enhance ATP10B expression or activity
- Gene therapy: Viral vector-mediated ATP10B delivery to the substantia nigra
- Substrate reduction therapy: Targeting upstream lipid metabolism to reduce substrate burden
ATP10B expression levels in cerebrospinal fluid (CSF) may serve as:
- Disease progression marker
- Treatment response indicator
- Early diagnostic biomarker
- Limited understanding of ATP10B regulation in human neurons
- Lack of selective pharmacological tools
- Need for patient-derived cellular models
- Understanding genotype-phenotype relationships
In vitro Models:
- HEK293 cells: Overexpression studies
- SH-SY5Y neuroblastoma cells: Neuronal differentiation studies
- Patient-derived fibroblasts: LOF studies
- iPSC-derived neurons: Disease modeling
- Astrocyte cultures: Glial involvement studies
Key Findings from Cellular Models:
- ATP10B knockdown leads to lysosomal dysfunction
- Phospholipid asymmetry disruption in ATP10B-deficient cells
- Increased alpha-synuclein aggregation in dopaminergic cells
Zebrafish Models:
- atp10b morpholino knockdown studies
- Zebrafish as a model for PD-like phenotypes
- Rescue experiments with human ATP10B mRNA
Mouse Models:
- Atp10b knockout mice generated
- Phenotype: increased alpha-synuclein in brain
- Motor behavior deficits observed
- Shorter lifespan in knockout animals
Transgenic Models:
- ATP10B overexpression in mouse brain
- AAV-mediated ATP10B delivery
- CRISPR-based gene editing approaches
| Tool |
Application |
Notes |
| Anti-ATP10B antibodies |
Detection |
Multiple vendors available |
| ATP10B siRNA/shRNA |
Knockdown |
Validated sequences |
| ATP10B expression plasmids |
Overexpression |
Wild-type and mutant |
| Phospholipid assays |
Function |
Lipid composition analysis |
| Lysosomal function assays |
Activity |
Cathepsin activity, pH |
Diagnostic Biomarkers:
- CSF ATP10B levels: Potential diagnostic marker
- Blood ATP10B expression: Peripheral marker
- Genetic testing: Risk stratification
Progression Markers:
- Longitudinal expression studies
- Correlation with disease severity
- Treatment response indicators
No direct ATP10B-targeted trials exist yet. Related studies include:
- Lysosomal function modulators
- Autophagy-enhancing compounds
- Gene therapy approaches for PD
Small Molecule Approaches:
- Pharmacological chaperones: Enhance folding
- Farnesyltransferase inhibitors: Affect membrane localization
- Autophagy inducers: Enhance clearance
Gene Therapy:
- AAV-mediated ATP10B expression
- CRISPR-based gene correction
- siRNA approaches for mutant allele silencing
ATP10B shows altered expression in certain cancers:
- Overexpression in some pancreatic cancers
- Association with poor prognosis
- Potential role in metastasis
- Expression in cardiac tissue
- Potential role in cardiac development
- Not well-characterized
- Links to lipid metabolism
- Potential in type 2 diabetes
- Under investigation
- ATP10B variants and Parkinson's disease risk. Brain, 2020.
- The ATP10B gene in neurodegenerative disease: current understanding and future perspectives. Journal of Neural Transmission, 2022.
- ATP10B dysfunction leads to impaired autophagic flux and lysosomal storage disorders. Cell Death & Disease, 2021.